Vischer advised CombiGene in its agreement with Spark Therapeutics

CombiGene and Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to the fight against genetic diseases, have entered into an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, a gene therapy for the treatment of drug-resistant focal epilepsy.
The agreement gives Spark an exclusive worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to conduct certain aspects of the preclinical program in collaboration with Spark.  

Under the terms of the contract, CombiGene is entitled to up to USD 328.5 million excluding royalties, of which USD 8.5 million upon signing and up to USD 50 million upon reaching preclinical and clinical milestones. CombiGene will also be reimbursed for certain approved R&D expenses. After commercialization, CombiGene is entitled to tiered license fees in the mid-single digit to low double digit range based on net sales.

Vischer partner Stefan Kohler (intellectual property law, pictured) advised CombiGene on negotiating the license agreement with the Swedish law firm Setterwalls (Stockholm).